Recap: Entrada Therapeutics Q4 Earnings
Portfolio Pulse from Benzinga Insights
Entrada Therapeutics (NASDAQ:TRDA) reported Q4 earnings with a significant miss on estimated earnings by -71.0%, posting an EPS of $-0.29 against an estimate of $-0.17. However, revenue saw an increase of $41.85 million from the same period last year. Despite beating EPS estimates last quarter, the share price dropped by 1.0% the following day.
March 13, 2024 | 1:35 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Entrada Therapeutics reported a significant miss in Q4 earnings with an EPS of $-0.29, far below the estimated $-0.17, but showed a revenue increase of $41.85 million from the previous year.
The significant miss in estimated earnings is likely to negatively impact investor confidence and could lead to a short-term decrease in stock price, similar to the reaction observed in the previous quarter despite beating EPS estimates. The increase in revenue may provide some buffer, but the large miss in earnings expectations typically has a more immediate negative effect on stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100